IP Library Granted Patent US 9,931,316
Granted Patent B2
US 9,931,316 · App. 14/853,932 · Granted Apr 3, 2018

Antiviral activity from medicinal mushrooms and their active constituents

Inventor: Paul Edward Stamets (Shelton, WA)
A61K31/37A61K31/05A61K31/12A61K31/192A61K31/352A61K31/7048A61K36/06A61K36/07A61K36/074
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,931,316
App. No.
14/853,932
Granted
Apr 3, 2018
Kind
B2
Abstract

Compounds having unique antiviral properties found in mushroom mycelium and their analogs are extracted, concentrated, isolated or manufactured to create compositions useful in preventing the spread and proliferation of various viruses afflicting animals, particularly viruses harming humans, pigs, birds, bats and bees. Such compounds and compositions can be used individually or in combination with known medicines or natural products to improve health.

Claims (18)

1. A method for treating a pathogenic virus infection comprising: administering about 0.1 g to about 2.0 g per day of an antiviral compound comprising syringic acid, trans-cinnamic acid, trans-ferulic acid, or salts thereof to a patient suffering from a viral replication of human Papillomavirus (HPV);

wherein

syringic acid, trans-cinnamic, acid and trans-ferulic acid have an antiviral effect Selectivity Index 50 (SI 50 )≥10 against the human papillomavirus (HPV).

2. The method of claim 1 ,

wherein syringic acid has an antiviral effect Selectivity Index 50 (SI 50 )≥30 against the human papillomavirus (HPV); and

trans-cinnamic acid and trans-ferulic acid have an antiviral effect Selectivity Index 50 (SI 50 )≥100 against the human papillomavirus (HPV).

3. The method of claim 1 , wherein the antiviral compound additionally has an antibacterial effect.

4. A method for treating a pathogenic virus infection comprising: administering a dose of an antiviral composition comprising about 0.1 g to about 2.0 g per day of syringic acid, trans-cinnamic acid, trans-ferulic acid, or salts thereof for a period of time from 10 to 60 days to a patient suffering from a viral replication of human Papillomavirus (HPV);

wherein

syringic acid, trans-cinnamic acid, and trans-ferulic acid have an antiviral effect Selectivity Index 50 (SI 50 )≥10 against the human papillomavirus (HPV).

5. The method of claim 4 , wherein the dose is about 0.1 to 1.5 grams per day.

6. The method of claim 4 , wherein the dose is about 0.25 to 1.4 grams per day.

7. The method of claim 4 , wherein the dose is about 1,000 mg per day.

8. The method of claim 4 ,

wherein syringic acid has an antiviral effect Selectivity Index 50 (SI 50 )≥30 against the human papillomavirus (HPV); and

trans-cinnamic acid and trans-ferulic acid have an antiviral effect Selectivity Index 50 (SI 50 )≥100 against the human papillomavirus (HPV).

9. The method of claim 4 , wherein the composition additionally has an antibacterial effect.

10. A method for treating a pathogenic virus infection comprising: administering about 0.1 g to about 2.0 g per day of syringic acid, trans-cinnamic acid, trans-ferulic acid, or salts thereof to a patient suffering from a viral replication of human Papillomavirus (HPV).

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 7, 2021
From: STAMETS, PAUL E.
To: TURTLE BEAR HOLDINGS, LLC
Reel/Frame 055960/0665 →
Continuity (2)
Provisional Application 62140459 · Mar 31, 2015
Related Publication 20160000754A1 · Jan 7, 2016